Compare DexCom, Inc. (DXCM) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs TORM plc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while TORM plc trades at $39.91 (market cap $4.12B). The key difference: DexCom, Inc. is far larger — about 7.7× TORM plc's market cap, and TORM plc pays a 11.03% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and TORM plc for 23 Days on average.
| DXCM | TRMD | |
|---|---|---|
Market Cap | $31.86B | $4.12B |
Volume | 3,607,070 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $92.34 | $41.05 |
52-Week Low | $54.84 | $19.39 |
Typical Hold Time | 62 Days | 23 Days |
Enterprise Value | $31.32B | $4.83B |
Dividend Yield | — | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
TRMD trades at $38.92, down 0.33% on the day, with strong profitability metrics including 35.52% net income margin and 26.84% ROE. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI suggests mild overbought conditions. Recent earnings showed mixed results with Q2 2026 missing expectations, while analyst consensus remains unanimously bullish with 100% buy ratings. The company maintains robust cash flow generation with $710M operating cash flow projected for 2026.
TRMD presents attractive valuation with P/E of 6.4 and EV/EBITDA of 5.11, supported by strong dividend yield from upcoming $2.40 payment. Key risks include spot rate volatility in tanker markets and recent insider selling activity. The fundamental outlook remains positive given projected revenue growth to $1.8B in 2026, though investors should monitor freight rate trends and competitive pressures in the product tanker sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
